Abstrakt

Przypisy

• 1. Bagrov A.Y., Shapiro J.I., Fedorova O.V.: Endogenous cardiotonicsteroids: physiology, pharmacology, and novel therapeutic targets.Pharmacol. Rev., 2009; 61: 9-38
  Google Scholar
• 2. Balzan S., Nicolini G., Bellitto L., Ghione S., Biver P., Montali U.:Effect of canrenone on the digitalis site of Na+/K+-ATPase in humanplacental membranes and in erythrocytes. J. Cardiovasc. Pharmacol.,2003; 42: 32-36
  Google Scholar
• 3. Cherniavsky-Lev M., Golani O., Karlish S.J., Garty H.: Ouabaininducedinternalization and lysosomal degradation of the Na+/K+-ATPase. J. Biol. Chem., 2014; 289: 1049-1059
  Google Scholar
• 4. Cutler J.A., Follmann D., Allender P.S.: Randomized trials of sodiumreduction: an overview. Am. J. Clin. Nutr., 1997; 65 (Suppl. 2):643S-651S
  Google Scholar
• 5. Dahl L.K.: Possible role of chronic excess salt consumption inthe pathogenesis of essential hypertension. Am. J. Cardiol., 1961;8: 571-575
  Google Scholar
• 6. Dahl L.K., Knudsen K.D., Heine M., Leitl G.: Effects of chronicexcess salt ingestion. Genetic influence on the development of salthypertension in parabiotic rats: evidence for a humoral factor. J.Exp. Med., 1967; 126: 687-699
  Google Scholar
• 7. de Wardener H.E., Clarkson E.M.: Concept of natriuretic hormone.Physiol. Rev., 1985; 65: 658-759
  Google Scholar
• 8. Drummond C.A., Buddny G., Haller S.T., Liu J., Yan Y., Xie Z., MalhotraD., Shapiro J.I., Tian J.: Gender differences in the developmentof uremic cardiomyopathy following partial nephrectomy: Role ofprogesterone. J. Hypertens., 2013; 2: 109
  Google Scholar
• 9. Elkareh J., Kennedy D.J., Yashaswi B., Vetteth S., Shidyak A., KimE.G., Smaili S., Periyasamy S.M., Hariri I.M., Fedorova L., Liu J., WuL., Kahaleh M.B., Xie Z., Malhotra D., Fedorova O.V., Kashkin V.A.,Bagrov A.Y., Shapiro J.I.: Marinobufagenin stimulates fibroblast collagenproduction and causes fibrosis in experimental uremic cardiomyopathy.Hypertension, 2007; 49: 215-224
  Google Scholar
• 10. Fedorova L.V., Raju V., El-Okdi N., Shidyak A., Kennedy D.J.,Vetteth S., Giovannucci D.R., Bagrov A.Y., Fedorova O.V., ShapiroJ.I., Malhotra D.: The cardiotonic steroid hormone marinobufagenininduces renal fibrosis: implication of epithelial-to-mesenchymaltransition. Am. J. Physiol. Renal Physiol., 2009; 296: F922-F934
  Google Scholar
• 11. Fraser C.L., Arieff A.I.: Na-K-ATPase activity decreases with agingin female rat brain synaptosomes. Am. J. Physiol. Renal Physiol.,2001; 281: F674-F678
  Google Scholar
• 12. Funder J.W.: Aldosterone, salt and cardiac fibrosis. Clin. Exp.Hypertens., 1997; 19: 885-899
  Google Scholar
• 13. Gottlieb S.S., Rogowski A.C., Weinberg M., Krichten C.M., HamiltonB.P., Hamlyn J.M.: Elevated concentrations of endogenousouabain in patients with congestive heart failure. Circulation, 1992;86: 420-425
  Google Scholar
• 14. Haller S.T., Drummond C.A., Yan Y., Liu J., Tian J., Malhotra D.,Shapiro J.I.: Passive immunization against marinobufagenin attenuatesrenal fibrosis and improves renal function in experimentalrenal disease. Am. J. Hypertens., 2014; 27: 603-609
  Google Scholar
• 15. Haller S.T., Kennedy D.J., Shidyak A., Budny G.V., Malhotra D.,Fedorova O.V., Shapiro J.I., Bagrov A.Y.: Monoclonal antibody againstmarinobufagenin reverses cardiac fibrosis in rats with chronic renalfailure. Am. J. Hypertens., 2012; 25: 690-696
  Google Scholar
• 16. Jablonski K.L., Fedorova O.V., Racine M.L., Geolfos C.J., GatesP.E., Chonchol M., Fleenor B.S., Lakatta E.G., Bagrov A.Y., Seals D.R.:Dietary sodium restriction and association with urinary marinobufagenin,blood pressure, and aortic stiffness. Clin. J. Am. Soc. Nephrol.,2013; 8: 1952-1959
  Google Scholar
• 17. Jansson K., Nguyen A.N., Magenheimer B.S., Reif G.A., AramadhakaL.R., Bello-Reuss E., Wallace D.P., Calvet J.P., Blanco G.: Endogenousconcentrations of ouabain act as a cofactor to stimulatefluid secretion and cyst growth of in vitro ADPKD models via cAMPand EGFR-Src-MEK pathways. Am. J. Physiol. Renal Physiol., 2012;303: F982-F990
  Google Scholar
• 18. Kawamoto E.M., Munhoz C.D., Lepsch L.B., de Sa Lima L., GlezerI., Markus R.P., de Silva C.L., Camarini R., Marcourakis T., Scavone C.:Age-related changes in cerebellar phosphatase-1 reduce Na,K-ATPaseactivity. Neurobiol. Aging, 2008; 29: 1712-1720
  Google Scholar
• 19. Kennedy D.J., Vetteth S., Periyasamy S.M., Kanj M., Fedorova L.,Khouri S., Kahaleh M.B., Xie Z., Malhotra D., Kolodkin N.I., LakattaE.G., Fedorova O.V., Bagrov A.Y., Shapiro J.I.: Central role for thecardiotonic steroid marinobufagenin in the pathogenesis of experimentaluremic cardiomyopathy. Hypertension, 2006; 47: 488-495
  Google Scholar
• 20. Koleganova N., Benz K., Piecha G., Ritz E., Amann K.: Renal, cardiovascularand metabolic effects of fetal programming. Nephrol.Dial. Transplant., 2012; 27: 3003-3007
  Google Scholar
• 21. Koleganova N., Piecha G., Ritz E., Becker L.E., Muller A., WeckbachM., Nyengaard J.R., Schirmacher P., Gross-Weissmann M.L.: Both highand low maternal salt intake in pregnancy alter kidney developmentin the offspring. Am. J. Physiol. Renal. Physiol., 2011; 301: F344-F354
  Google Scholar
• 22. Kolmakova E.V., Haller S.T., Kennedy D.J., Isachkina A.N., BudnyG.V., Frolova E.V., Piecha G., Nikitina E.R., Malhotra D., FedorovaO.V., Shapiro J.I., Bagrov A.Y.: Endogenous cardiotonic steroids inchronic renal failure. Nephrol. Dial. Transplant., 2011; 26: 2912-2919
  Google Scholar
• 23. Laragh J.H., Sealey J.E., Niarchos A.P., Pickering T.G.: The vasoconstriction-volumespectrum in normotension and in the pathogenesisof hypertension. Fed. Proc., 1982; 41: 2415-2423
  Google Scholar
• 24. Liu C., Bai Y., Chen Y., Wang Y., Sottejeau Y., Liu L., Li X., LingrelJ.B., Malhotra D., Cooper C.J., Shapiro J.I., Xie Z.J., Tian J.: Reductionof Na/K-ATPase potentiates marinobufagenin-induced cardiacdysfunction and myocyte apoptosis. J. Biol. Chem., 2012; 287:16390-16398
  Google Scholar
• 25. Manunta P., Stella P., Rivera R., Ciurlino D., Cusi D., FerrandiM., Hamlyn J.M., Bianchi G.: Left ventricular mass, stroke volume,and ouabain-like factor in essential hypertension. Hypertension,1999; 34: 450-456
  Google Scholar
• 26. Nguyen A.N., Jansson K., Sánchez G., Sharma M., Reif G.A., WallaceD.P., Blanco G.: Ouabain activates the Na-K-ATPase signalosometo induce autosomal dominant polycystic kidney disease cell proliferation.Am. J. Physiol. Renal Physiol., 2011; 301: F897-F906
  Google Scholar
• 27. Nikitina E.R., Mikhailov A.V., Nikandrova E.S., Frolova E.V.,Fadeev A.V., Shman V.V., Shilova V.Y., Tapilskaya N.I., Shapiro J.I.,Fedorova O.V., Bagrov A.Y.: In preeclampsia endogenous cardiotonicsteroids induce vascular fibrosis and impair relaxation of umbilicalarteries. J. Hypertens., 2011; 29: 769-776
  Google Scholar
• 28. Norgaard A., Bagger J.P., Bjerregaard P., Baandrup U., Kjeldsen K.,Thomsen P.E.: Relation of left ventricular function and Na,K-pumpconcentration in suspected idiopathic dilated cardiomyopathy. Am.J. Cardiol., 1988; 61: 1312-1315
  Google Scholar
• 29. Piecha G., Koleganova N., Ritz E., Müller A., Fedorova O.V., BagrovA.Y., Lutz D., Schirmacher P., Gross-Weissmann M.L.: High salt intakecauses adverse fetal programming – vascular effects beyond bloodpressure. Nephrol. Dial. Transplant., 2012; 27: 3464-3476
  Google Scholar
• 30. Reckelhoff J.F.: Gender differences in the regulation of bloodpressure. Hypertension, 2001; 37: 1199-1208
  Google Scholar
• 31. Sato A., Saruta T.: Aldosterone-induced organ damage: plasmaaldosterone level and inappropriate salt status. Hypertens. Res.,2004; 27: 303-310
  Google Scholar
• 32. Schoner W., Scheiner-Bobis G.: Endogenous and exogenous cardiacglycosides: their roles in hypertension, salt metabolism, and cellgrowth. Am. J. Physiol. Cell Physiol., 2007; 293: C509-C536
  Google Scholar
• 33. Semb S.O., Lunde P.K., Holt E., Tonnessen T., Christensen G.,Sejersted O.M.: Reduced myocardial Na+, K+-pump capacity in congestiveheart failure following myocardial infarction in rats. J. Mol.Cell. Cardiol., 1998; 30: 1311-1328
  Google Scholar
• 34. Staessen J.A., Thijs L., Stolarz-Skrzypek K., Bacchieri A., BartonJ., Espositi E.D., de Leeuw P.W., Dluzniewski M., Glorioso N., JanuszewiczA., Manunta P., Milyagin V., Nikitin Y., Soucek M., Lanzani C.,et al.: Main results of the ouabain and adducin for Specific Interventionon Sodium in Hypertension Trial (OASIS-HT): a randomizedplacebo-controlled phase-2 dose-finding study of rostafuroxin.Trials, 2011; 12: 13
  Google Scholar
• 35. Tian J., Haller S., Periyasamy S., Brewster P., Zhang H., AdlakhaS., Fedorova O.V., Xie Z.J., Bagrov A.Y., Shapiro J.I., Cooper C.J.: Renalischemia regulates marinobufagenin release in humans. Hypertension,2010; 56: 914-919
  Google Scholar
• 36. Tian J., Li X., Liang M., Liu L., Xie J.X., Ye Q., Kometiani P., TillekeratneM., Jin R., Xie Z.: Changes in sodium pump expression dictatethe effects of ouabain on cell growth. J. Biol. Chem., 2009; 284:14921-14929
  Google Scholar
• 37. Tian J., Shidyak A., Periyasamy S.M., Haller S., Taleb M., El-OkdiN., Elkareh J., Gupta S., Gohara S., Fedorova O.V., Cooper C.J., Xie Z.,Malhotra D., Bagrov A.Y., Shapiro J.I.: Spironolactone attenuatesexperimental uremic cardiomyopathy by antagonizing marinobufagenin.Hypertension, 2009; 54: 1313-1320
  Google Scholar
• 38. Tirupattur P.R., Ram J.L., Standley P.R., Sowers J.R.: Regulation ofNa+,K+-ATPase gene expression by insulin in vascular smooth musclecells. Am. J. Hypertens., 1993; 6: 626-629
  Google Scholar
• 39. Weinberger M.H.: Salt sensitivity of blood pressure in humans.Hypertension, 1996; 27: 481-490
  Google Scholar

Pełna treść artykułu